T-Bird Pharma Inc., a pharmaceutical company focused on developing premium quality medical marijuana products, is pleased to announce that its shares will begin trading on the TSX Venture Exchange on September 9, 2014. The Company’s wholly-owned subsidiary, Thunderbird Biomedical Inc. (“Thunderbird”), is licensed under the Marihuana for Medical Purposes Regulations (Canada) (“MMPR”) overseen by Health Canada. T-Bird will be British Columbia’s first publicly traded medical marijuana company. Thunderbird is one of 13 companies in Canada licensed under the MMPR.
On September 5, 2014, the Company announced the completion of its $3 million equity financing. The agent on the financing was Richardson GMP Ltd. and the proceeds will enable the Company to bring online two additional grow rooms at their existing Victoria based facility and accelerate expansion to a second larger facility, also located on Vancouver Island, as the Company moves towards commercialization. Additional updates on the new facility will be available in the coming weeks.
“After spending much of the past year assembling our team and developing our technology driven processes we are excited to be moving the Company forward towards providing a premium quality medical marijuana product to Canadian patients under the MMPR. Our pharmaceutical grade approach aims to ensure repeatable, scalable and consistent medical marijuana products,” said Rob Gagnon, founder of Thunderbird and CEO of T-Bird. “Over the next few months we will be working towards further expansion of not only our growing facilities, but also adding key scientific advisors to our team”.
The Company has an existing portfolio of over 60 high grade premium medicinal strains of marijuana, which it refers to internally as “varietals”, and which includes such well known strains as: Island Honey, Pink Kush and Blue God. Thunderbird’s focus is on working with BC developed strains. BC has developed a reputation for expertise in this subject matter and strains that have become synonymous with quality.
“Our business model has been to start with a small facility to perfect our processes which have been architected to be scalable and repeatable. We believe the market opportunity is only going to grow and we intend to be well positioned to increase capacity while ensuring quality of product” noted incoming Chairman, David Raffa. Added Raffa, “With the initial financing now done and a strong financial partner in Richardson GMP, we are well positioned to do what is necessary to grow the business.”
